Bevacizumab for pediatric radiation necrosis.

ABSTRACT:

Background

Radiation necrosis is a frequent complication occurring after the treatment of pediatric brain tumors; however, treatment options remain a challenge. Bevacizumab is an anti-VEGF monoclonal antibody that has been shown in small adult cohorts to confer a benefit, specifically a reduction in steroid usage, but its use in children has not been well described.

Methods

We describe our experience with bevacizumab use for symptomatic radiation necrosis at 5 institutions including patients treated after both initial irradiation and reirradiation.

Results

We identified 26 patients treated with bevacizumab for symptomatic radiation necrosis, with a wide range of underlying diagnoses. The average age at diagnosis of radiation necrosis was 10.7 years, with a median time

SUBMITTER: Baroni LV 

PROVIDER: S-EPMC7393279 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature